Center for Drug Design

Therapeutic Approaches: Small Molecules, Drug Delivery, Drug Devices, Drug Design/Discovery

Therapeutic Areas of Expertise: Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology, Pain, Regenerative Medicine, Antidotes, herbicide

Center/Program Highlights:Center for Drug Design (CDD) is lead by Robert Vince, developer of Ziagen?, an HIV therapy licensed by GSK. The CDD concentrates on anti-viral/anti-bacterial, neurological, and anti-cancer areas. Our specialized foci are 1) design of small molecules for selected targets, 2) target validation, 3) optimization of drug deliveries through PK & ADMET studies.

Sources of Funding: Federal/State, Industry Partnerships, Disease Foundations, University, Royalties from licensed drug therapy

Industrial Partnerships: GSK (Ziagen?) Vytacera Pharma, Inc. (Anti-cyanide therapy) Private company (herbicide process)


Institutional Affiliation(s): University of Minnesota

Center for Drug Design
516 Delaware St SE, MMC 204
Minnesota, 55455
United States

Center/Program Start Date: 2002

Number of Employees: 60